Table 1 Clinical correlates according to the TMB status.
From: Characterization of pancreatic cancer with ultra-low tumor mutational burden
Variable | All | TMB | P-value | |
|---|---|---|---|---|
Ultra-low (< 1.0) | Low (< 5.0, ≥ 1.0) | |||
N = 93 | N = 74 | N = 19 | ||
Patient characteristics | ||||
Age (years) | 71 (64–77) | 71 (64–77) | 73 (64–78) | 0.853 |
Sex male | ||||
Male | 55 (59%) | 46 (62%) | 9 (47%) | 0.242 |
Female | 38 (41%) | 28 (38%) | 10 (53%) | |
CA19-9 level (units/ml) | 124 (32–577) | 121 (31–596) | 144 (31–507) | 0.943 |
Peri-operative management | ||||
Resectability status | ||||
R | 82 (88%) | 68 (92%) | 14 (74%) | 0.028 |
BR | 11 (12%) | 6 (8%) | 5 (26%) | |
Neoadjuvant therapy | ||||
Performed | 11 (12%) | 8 (11%) | 3 (16%) | 0.549 |
Adjuvant therapy | ||||
Performed | 65 (70%) | 53 (72%) | 12 (63%) | 0.478 |
Pathological findings | ||||
Location | ||||
Ph | 59 (63%) | 46 (62%) | 13 (68%) | 0.613 |
Pbt | 34 (37%) | 28 (38%) | 6 (32%) | |
Histological type | ||||
Adenocarcinoma | 83 (89%) | 70 (95%) | 13 (68%) | 0.003 |
Adenosquamous | 10 (11%) | 4 (5%) | 6 (32%) | |
Primary tumor status | ||||
T1 | 2 (2%) | 2 (3%) | 0 (0%) | 0.368 |
T2 | 63 (68%) | 52 (70%) | 11 (58%) | |
T3 | 28 (31%) | 20 (27%) | 8 (42%) | |
Nodal status | ||||
N0 | 23 (25%) | 18 (24%) | 5 (26%) | 0.977 |
N1 | 41 (44%) | 33 (45%) | 8 (42%) | |
N2 | 29 (31%) | 23 (31%) | 6 (32%) | |
Metastasis | ||||
M0 | 89 (96%) | 70 (95%) | 19 (100%) | 0.300 |
M1 | 4 (4%) | 4 (5%) | 0 (0%) | |
Resection status | ||||
R0 | 89 (96%) | 70 (95%) | 19 (100%) | 0.300 |
R1 | 4 (4%) | 4 (5%) | 0 (0%) | |
